Related references
Note: Only part of the references are listed.Sentinel joint scoring in rheumatoid arthritis: an individualized power Doppler assessment strategy
Daniel Kuo et al.
CLINICAL RHEUMATOLOGY (2021)
Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis
H. B. Hammer et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2021)
Contemporary imaging of rheumatoid arthritis: Clinical role of ultrasound and MRI
Veena K. Ranganath et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2020)
Ultrasound detects synovitis in replaced and other surgically operated joints in rheumatoid arthritis patients
Evan A. Choate et al.
BMC RHEUMATOLOGY (2020)
Ultrasound is more reliable than inflammatory parameters to evaluate disease activity in patients with RA receiving tocilizumab therapy
Wen-Chan Chiu et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2018)
Joint-specific assessment of swelling and power Doppler in obese rheumatoid arthritis patients
Erin M. Bauer et al.
BMC MUSCULOSKELETAL DISORDERS (2017)
Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients
J. R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2015)
Confirmation of effectiveness of tocilizumab by ultrasonography and magnetic resonance imaging in biologic agent-naive early-stage rheumatoid arthritis patients
Shin-Ya Kawashiri et al.
MODERN RHEUMATOLOGY (2015)
The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
Philip G. Conaghan et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis
Huong Nguyen et al.
RHEUMATOLOGY (2014)
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
Vibeke Strand et al.
RHEUMATOLOGY (2012)
Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab-preliminary data
Maasa Hama et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Interleukin-6 Receptor Inhibition With Tocilizumab and Attainment of Disease Remission in Rheumatoid Arthritis The Role of Acute-Phase Reactants
Josef S. Smolen et al.
ARTHRITIS AND RHEUMATISM (2011)
Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger
Tamotsu Kamishima et al.
SKELETAL RADIOLOGY (2011)
Very Early Improvements in the Wrist and Hand Assessed by Power Doppler Sonography Predicting Later Favorable Responses in Tocilizumab-Treated Patients With Rheumatoid Arthritis
Kensuke Kume et al.
ARTHRITIS CARE & RESEARCH (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
Gert J. D. Bergman et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
Evaluation of a Novel 7-Joint Ultrasound Score in Daily Rheumatologic Practice: A Pilot Project
M. Backhaus et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
The Disease Activity Score and the EULAR Response Criteria
Jaap Fransen et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Share Paper
